| Title: |
Pharmacokinetics and Pharmacodynamics of Levetiracetam in Neonatal Seizures: What We Still Need to Know. |
| Authors: |
Hughes, Shayne; Blumenthal, Max; Johnson, Alexis; Limjoco, Jamie; Sin Yin Lim |
| Source: |
Journal of Pediatric Pharmacology & Therapeutics; 2025, Vol. 30 Issue 2, p170-181, 12p |
| Subject Terms: |
OFF-label use (Drugs); ANTICONVULSANTS; LEVETIRACETAM; NEWBORN infants; SEIZURES (Medicine) |
| Abstract: |
Neonatal seizures affect 1 to 4 neonates per 1000 live births and are associated with increased mortality and neurological impairment. Currently, phenobarbital is recommended as the first-line treatment; however, its limited efficacy and serious safety concerns are significant drawbacks. Levetiracetam, a newer generation anti-seizure medication with minimal reported adverse effects, is commonly used off label for the treatment of neonatal seizures. Earlier studies showed limited efficacy of levetiracetam in neonatal seizures; however, these studies were limited by the lack of pharmacokinetic-pharmacodynamic data for larger doses (>60 mg/kg). The pharmacokinetics of levetiracetam differ in neonates compared to children and adults. In neonates, the volume of distribution of levetiracetam can exceed that in children and adults. By 7 days of postnatal age, the clearance approaches that of children, which also exceeds the clearance reported in adults. There are limited pharmacodynamic studies of levetiracetam in neonatal seizures. Because the pathophysiology of seizures and the treatment goals in neonates differ from those in children and adults, critical information on the pharmacodynamics of levetiracetam at larger doses is still needed to confirm its efficacy or lack thereof. [ABSTRACT FROM AUTHOR] |
| : |
Copyright of Journal of Pediatric Pharmacology & Therapeutics is the property of Pediatric Pharmacy Advocacy Group and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |